MOPE Clinic Publishes PSA Monitoring Guide for Men Considering Testosterone Therapy

MOPE Clinic in Metairie has released an educational PSA and prostate-health tip sheet for men considering or receiving testosterone replacement therapy. The guidance focuses on baseline testing, shared decision-making and when PSA changes may warrant follow-up during TRT.

Why it matters: - Men considering testosterone replacement therapy often need help separating PSA testing, prostate cancer concerns and routine monitoring. - The clinic’s guidance highlights that PSA is only one part of TRT care, alongside symptoms, testosterone levels, blood counts and individual prostate-cancer risk. - The Endocrine Society has said TRT should start with an accurate diagnosis and appropriate monitoring, while long-term prostate safety questions remain unresolved.

What happened: - MOPE Clinic, a concierge health clinic in Metairie serving Greater New Orleans and South Louisiana, issued an educational PSA and prostate-health tip sheet for men considering or receiving medically supervised testosterone replacement therapy. - The clinic framed the release as a practical guide for men navigating baseline testing, follow-up monitoring and prostate-risk discussions. - MOPE Clinic also pointed readers to its related article for more information.

The details: - PSA stands for prostate-specific antigen, a protein made primarily by prostate tissue and measured through a blood test. - An elevated PSA does not, by itself, diagnose prostate cancer. - Noncancerous factors that can affect PSA include benign prostate enlargement, inflammation, infection, age and other clinical circumstances. - Clinicians generally interpret PSA alongside prior values, symptoms, medical history, family history and overall prostate-cancer risk. - Chris Rue, FNP-C, said PSA should not be viewed as an isolated number and should be interpreted in the context of the patient’s history, prior testing, symptoms and overall risk. - Testosterone interacts with prostate tissue, which is why prostate health is part of TRT decision-making. - The Endocrine Society recommends against starting testosterone therapy in certain situations without further evaluation, including known prostate cancer, a palpable prostate nodule or induration, a PSA level above specified thresholds and certain other medical conditions. - For men ages 55 to 69 considering TRT who have a life expectancy greater than 10 years, the guideline recommends discussing the potential benefits and risks of evaluating prostate-cancer risk and monitoring. - Men ages 40 to 69 who are at increased prostate-cancer risk may warrant that discussion earlier. - The guidance says monitoring can include prostate-risk assessment before treatment and again during the first year after TRT begins. - Depending on the individual, follow-up may include PSA testing and other prostate evaluation as clinically appropriate. - Certain findings in the first year may prompt urologic consultation, including a confirmed PSA increase greater than 1.4 ng/mL above baseline, a confirmed PSA concentration above 4.0 ng/mL, or a prostate abnormality on examination. - An unexpected PSA result may need to be confirmed before the next step is chosen. - After the initial monitoring period, prostate screening generally follows age- and risk-based prostate-cancer screening recommendations. - Current evidence does not support the simple claim that medically supervised TRT automatically causes prostate cancer. - The Endocrine Society said in July 2026 that long-term safety, including prostate-cancer risk, remains unestablished. - Monitoring may also include testosterone levels, hematocrit and other clinical measures. - Hematocrit is the percentage of blood volume made up of red blood cells, and testosterone therapy can increase red blood cell production in some men. - Symptoms and treatment response matter because a testosterone level alone does not show energy, sexual function, mood, sleep, body composition, treatment tolerability or other health conditions. - The clinic says organized records can improve follow-up, especially previous PSA results, family history and an updated medication list that includes testosterone formulation, dose and schedule. - New or worsening urinary symptoms to report include trouble starting urination, weak flow, increased frequency, urgency, incomplete bladder emptying and increased nighttime urination. - Men should not change testosterone treatment based on one laboratory result alone. - Helpful pre-TRT discussion topics include the reason testosterone is low, whether the diagnosis has been confirmed appropriately, fertility plans, medical history, cardiovascular and blood-count considerations, prostate risk, expected monitoring, possible side effects and treatment goals.

Between the lines: - The release tries to correct a common misunderstanding: PSA testing and prostate cancer are related, but they are not the same thing. - The article also reinforces a broader theme in hormone care: a single lab value should not drive decisions without symptoms, baseline data and risk context. - The emphasis on shared decision-making suggests clinicians should individualize TRT monitoring rather than apply one universal testing schedule.

What's next: - Men already on TRT are being advised to discuss any unexpected PSA change with their clinician rather than stopping treatment on their own. - Depending on the result and medical history, next steps may include repeat testing, further evaluation or referral to a specialist. - Future prostate screening after the first year should continue under age- and risk-appropriate guidelines. - MOPE Clinic says concierge visits are available by appointment, with telemedicine available for eligible hormone-optimization patients depending on service, location and clinical requirements.

The bottom line: - MOPE Clinic’s message is straightforward: testosterone therapy should be guided by accurate diagnosis, individualized prostate-risk discussion and structured follow-up, not by PSA alone.